Bradwejn J - Search Results

1

Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze.

Vasar E, Lang A, Harro J, Kõks S, Volke V, Sihver S, Bourin M, Bradwejn J, Männistö PT. Vasar E, et al. Among authors: bradwejn j. Neuropeptides. 1994 Jan;26(1):39-45. doi: 10.1016/0143-4179(94)90091-4. Neuropeptides. 1994. PMID: 8159285

2

Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze.

Volke V, Kõks S, Vasar E, Bourin M, Bradwejn J, Männistö PT. Volke V, et al. Among authors: bradwejn j. Neuroreport. 1995 Jul 10;6(10):1413-6. doi: 10.1097/00001756-199507100-00013. Neuroreport. 1995. PMID: 7488737

3

Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.

Vasar E, Lang A, Harro J, Bourin M, Bradwejn J. Vasar E, et al. Among authors: bradwejn j. Neuropharmacology. 1994 Jun;33(6):729-35. doi: 10.1016/0028-3908(94)90112-0. Neuropharmacology. 1994. PMID: 7936110

4

Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation.

Harro J, Oreland L, Vasar E, Bradwejn J. Harro J, et al. Among authors: bradwejn j. Eur Neuropsychopharmacol. 1995 Dec;5(4):447-55. doi: 10.1016/0924-977x(95)00015-h. Eur Neuropsychopharmacol. 1995. PMID: 8998396

5

Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats.

Lang A, Harro J, Soosaar A, Kõks S, Volke V, Oreland L, Bourin M, Vasar E, Bradwejn J, Männistö PT. Lang A, et al. Among authors: bradwejn j. Naunyn Schmiedebergs Arch Pharmacol. 1995 Apr;351(4):363-70. doi: 10.1007/BF00169076. Naunyn Schmiedebergs Arch Pharmacol. 1995. PMID: 7630427

6

Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents.

Lang A, Soosaar A, Kõks S, Volke V, Bourin M, Bradwejn J, Vasar E. Lang A, et al. Among authors: bradwejn j. Pharmacol Toxicol. 1994 Sep-Oct;75(3-4):222-7. doi: 10.1111/j.1600-0773.1994.tb00351.x. Pharmacol Toxicol. 1994. PMID: 7800667

7

Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats.

Männistö PT, Lang A, Harro J, Peuranen E, Bradwejn J, Vasar E. Männistö PT, et al. Among authors: bradwejn j. Naunyn Schmiedebergs Arch Pharmacol. 1994 May;349(5):478-84. doi: 10.1007/BF00169136. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 8065461

8

CCK in animal and human research on anxiety.

Harro J, Vasar E, Bradwejn J. Harro J, et al. Among authors: bradwejn j. Trends Pharmacol Sci. 1993 Jun;14(6):244-9. doi: 10.1016/0165-6147(93)90020-k. Trends Pharmacol Sci. 1993. PMID: 8372405 Review.

9

Two faces of cholecystokinin: anxiety and schizophrenia.

Bourin M, Malinge M, Vasar E, Bradwejn J. Bourin M, et al. Among authors: bradwejn j. Fundam Clin Pharmacol. 1996;10(2):116-26. doi: 10.1111/j.1472-8206.1996.tb00154.x. Fundam Clin Pharmacol. 1996. PMID: 8737954 Review.

10

Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.

Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Shlik J, et al. Among authors: bradwejn j. J Psychiatry Neurosci. 1997 Nov;22(5):332-40. J Psychiatry Neurosci. 1997. PMID: 9401314 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters